相关实验视频
Updated: Feb 21, 2026

10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
23.3K
装有药物的纳米粒子减少了血小板聚合和血液凝结
Sarah Majin1, Afrida Malik1, Pratima Poudel1
1Department of Chemistry and Chemical & Biomedical Engineering, University of New Haven, West Haven, CT, United States.
Frontiers in medical technology
|February 20, 2026
概括
释放氧化的纳米颗粒通过抑制血小板激活和凝固,有效地防止血栓形成. 这些新型抗血小板脂质纳米颗粒为医疗器械提供了一个有前途的解决方案.
科学领域:
- 生物材料工程 生物材料工程
- 纳米技术纳米技术
- 心血管研究研究心血管研究
背景情况:
- 表面诱导的血栓形成是接触血液的医疗器械面临的主要挑战.
- 血小板激活和血块形成是器件相关血栓形成的关键驱动因素.
- 氧化 (NO) 是一种具有治疗潜力的天然抗血小板剂.
研究的目的:
- 开发和描述释放氧化的抗血小板脂质纳米颗粒 (抗PLT LNPs).
- 评估抗PLTLNP的抗血小板和抗凝剂疗效.
- 评估纳米颗粒的生物相容性和NO释放动力学.
主要方法:
- 抗PLTLNP的配方和物理化学表征.
- 在体外评估血小板聚合抑制.
- 使用激活凝血时间 (ACT) 评估哺乳动物细胞生物相容性和全血凝血.
主要成果:
- 抗PLT的LNP在22周内持续释放氧化.
- 纳米粒子显示出高的哺乳动物细胞生物相容性.
- 显著抑制血小板聚合 (高达84.4%) 和延长凝血时间 (ACT增加高达三倍).
结论:
- 无释放抗PLT的LNP有效抑制血小板激活和凝固.
- 这些纳米粒子保持生物相容性,提供了一种有针对性的方法来缓解血栓形成.
- 这些发现表明了改善接触血液的医疗设备的有希望的策略.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Formation of the Platelet Plug
9.8K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
9.8K
Site-Targeted Drug Delivery Systems: Polymeric Carriers
34
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
34
Modified-Release Drug Delivery Systems: Site-Targeted
30
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
30

